IL97312A - A method of generating a polypeptide in an eukaryotic vector AND recombinant surrogate cell containing an enhanced transcriptional control unit based on the primary late adenovirus coefficient - Google Patents
A method of generating a polypeptide in an eukaryotic vector AND recombinant surrogate cell containing an enhanced transcriptional control unit based on the primary late adenovirus coefficientInfo
- Publication number
- IL97312A IL97312A IL9731291A IL9731291A IL97312A IL 97312 A IL97312 A IL 97312A IL 9731291 A IL9731291 A IL 9731291A IL 9731291 A IL9731291 A IL 9731291A IL 97312 A IL97312 A IL 97312A
- Authority
- IL
- Israel
- Prior art keywords
- plasmid
- dna
- buffer
- polypeptide
- adenovirus
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6464—Protein C (3.4.21.69)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6456—Plasminogen activators
- C12N9/6459—Plasminogen activators t-plasminogen activator (3.4.21.68), i.e. tPA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21069—Protein C activated (3.4.21.69)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
- C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/30—Vector systems having a special element relevant for transcription being an enhancer not forming part of the promoter region
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/55—Vector systems having a special element relevant for transcription from bacteria
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
- C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/10—Vectors comprising a special translation-regulating system regulates levels of translation
- C12N2840/105—Vectors comprising a special translation-regulating system regulates levels of translation enhancing translation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Treatments For Attaching Organic Compounds To Fibrous Goods (AREA)
- Ultra Sonic Daignosis Equipment (AREA)
- Liquid Crystal Substances (AREA)
- Financial Or Insurance-Related Operations Such As Payment And Settlement (AREA)
- Superconductors And Manufacturing Methods Therefor (AREA)
- Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
- Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)
- Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
- Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US48408290A | 1990-02-23 | 1990-02-23 |
Publications (2)
Publication Number | Publication Date |
---|---|
IL97312A0 IL97312A0 (en) | 1992-05-25 |
IL97312A true IL97312A (en) | 1999-01-26 |
Family
ID=23922667
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL9731291A IL97312A (en) | 1990-02-23 | 1991-02-20 | A method of generating a polypeptide in an eukaryotic vector AND recombinant surrogate cell containing an enhanced transcriptional control unit based on the primary late adenovirus coefficient |
Country Status (12)
Country | Link |
---|---|
US (2) | US5573938A (fr) |
EP (1) | EP0445939B1 (fr) |
JP (1) | JP3014475B2 (fr) |
AT (1) | ATE153072T1 (fr) |
AU (1) | AU638796B2 (fr) |
CA (1) | CA2036913C (fr) |
DE (1) | DE69126053T2 (fr) |
ES (1) | ES2102385T3 (fr) |
GR (1) | GR3024137T3 (fr) |
HU (1) | HU215186B (fr) |
IE (1) | IE910612A1 (fr) |
IL (1) | IL97312A (fr) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU765709B2 (en) * | 1992-12-03 | 2003-09-25 | Genzyme Corporation | Gene therapy for cystic fibrosis |
US5618714A (en) * | 1993-12-15 | 1997-04-08 | Eli Lilly And Company | Methods for producing protein C |
EA002149B1 (ru) * | 1997-04-28 | 2001-12-24 | Эли Лилли Энд Компани | Улучшенные способы приготовления активированного белка с |
US6630137B1 (en) | 1997-04-28 | 2003-10-07 | Eli Lilly And Company | Activated protein C formulations |
WO1998055142A1 (fr) * | 1997-06-05 | 1998-12-10 | Eli Lilly And Company | Procede de traitement de troubles thrombotiques |
US6548296B1 (en) | 1997-07-23 | 2003-04-15 | Roche Diagnostics Gmbh | Methods for identifying human cell lines useful for endogenous gene activation, isolated human lines identified thereby, and uses thereof |
HUP0001237A3 (en) * | 1997-10-20 | 2002-01-28 | Lilly Co Eli | Methods for treating vascular disorders |
EP1124573A1 (fr) | 1998-10-22 | 2001-08-22 | Eli Lilly And Company | Methodes de traitement de la septicemie |
EP1128842B1 (fr) | 1998-11-13 | 2006-03-15 | Eli Lilly And Company | Utilisation de la proteine c pour la preparation d'un medicament pour le traitement de la thrombopenie immunitaire de l'heparine |
DE69906568T2 (de) | 1998-11-20 | 2004-02-12 | Eli Lilly And Co., Indianapolis | Behandlung von hämorrhagischem virusfieber mit protein c |
DK1133314T3 (da) | 1998-11-23 | 2003-04-14 | Lilly Co Eli | Protein C til behandling af seglcellesygdom og thalassæmi |
WO2001000798A2 (fr) * | 1999-06-25 | 2001-01-04 | Hybritech Incorporated | Clonage et expression de cathepsine k humaine dans des cellules mammaliennes |
US7204981B2 (en) | 2000-03-28 | 2007-04-17 | Eli Lilly And Company | Methods of treating diseases with activated protein C |
AU2001262939A1 (en) | 2000-05-24 | 2001-12-03 | Eli Lilly And Company | Formulations and use of activated protein c and protein c zymogen for treating hypercoagulable states |
ES2385251B1 (es) | 2009-05-06 | 2013-05-06 | Fundació Privada Institut D'investigació Biomèdica De Bellvitge | Adenovirus oncolíticos para el tratamiento del cáncer. |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4436815A (en) | 1981-11-27 | 1984-03-13 | Eli Lilly And Company | Method for stabilizing and selecting recombinant DNA containing host cells |
US4775624A (en) | 1985-02-08 | 1988-10-04 | Eli Lilly And Company | Vectors and compounds for expression of human protein C |
US4935349A (en) * | 1986-01-17 | 1990-06-19 | Zymogenetics, Inc. | Expression of higher eucaryotic genes in aspergillus |
US4775621A (en) | 1986-02-25 | 1988-10-04 | North Carolina State University | Method of distinguishing invasive E. coli that cause septicemia |
EP0245949B1 (fr) * | 1986-04-09 | 1997-10-29 | Eli Lilly And Company | Méthode d'utilisation des vecteurs d'expression eucaryotiques comportant les séquences stimulantes du virus BK |
US4992373A (en) | 1987-12-04 | 1991-02-12 | Eli Lilly And Company | Vectors and compounds for direct expression of activated human protein C |
US4981952A (en) | 1988-10-04 | 1991-01-01 | Eli Lilly And Company | Method for the purification of vitamin K-dependent proteins |
CA1332049C (fr) | 1988-10-07 | 1994-09-20 | Eli Lilly And Company | Expression eucaryotique |
US5043270A (en) * | 1989-03-31 | 1991-08-27 | The Board Of Trustees Of The Leland Stanford Junior University | Intronic overexpression vectors |
US5270178A (en) * | 1990-02-23 | 1993-12-14 | Eli Lilly And Company | Vectors and compounds for expression of zymogen forms of human protein C |
-
1991
- 1991-02-20 IL IL9731291A patent/IL97312A/en not_active IP Right Cessation
- 1991-02-22 DE DE69126053T patent/DE69126053T2/de not_active Expired - Fee Related
- 1991-02-22 AT AT91301451T patent/ATE153072T1/de not_active IP Right Cessation
- 1991-02-22 ES ES91301451T patent/ES2102385T3/es not_active Expired - Lifetime
- 1991-02-22 CA CA002036913A patent/CA2036913C/fr not_active Expired - Fee Related
- 1991-02-22 IE IE061291A patent/IE910612A1/en not_active IP Right Cessation
- 1991-02-22 JP JP3050647A patent/JP3014475B2/ja not_active Expired - Lifetime
- 1991-02-22 AU AU71306/91A patent/AU638796B2/en not_active Expired
- 1991-02-22 EP EP91301451A patent/EP0445939B1/fr not_active Expired - Lifetime
- 1991-02-22 HU HU91603A patent/HU215186B/hu not_active IP Right Cessation
-
1993
- 1993-12-01 US US08/160,450 patent/US5573938A/en not_active Expired - Lifetime
-
1995
- 1995-05-19 US US08/446,126 patent/US5661002A/en not_active Expired - Lifetime
-
1997
- 1997-07-16 GR GR970401787T patent/GR3024137T3/el unknown
Also Published As
Publication number | Publication date |
---|---|
DE69126053T2 (de) | 1997-09-25 |
CA2036913C (fr) | 1999-12-14 |
HU910603D0 (en) | 1991-09-30 |
HU215186B (hu) | 1998-10-28 |
US5573938A (en) | 1996-11-12 |
JPH05268981A (ja) | 1993-10-19 |
EP0445939A1 (fr) | 1991-09-11 |
ES2102385T3 (es) | 1997-08-01 |
HUT56885A (en) | 1991-10-28 |
DE69126053D1 (de) | 1997-06-19 |
AU638796B2 (en) | 1993-07-08 |
EP0445939B1 (fr) | 1997-05-14 |
GR3024137T3 (en) | 1997-10-31 |
US5661002A (en) | 1997-08-26 |
IL97312A0 (en) | 1992-05-25 |
IE910612A1 (en) | 1991-08-28 |
JP3014475B2 (ja) | 2000-02-28 |
CA2036913A1 (fr) | 1991-08-24 |
AU7130691A (en) | 1991-08-29 |
ATE153072T1 (de) | 1997-05-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5661002A (en) | Modified transcription control unit and uses thereof | |
US5770397A (en) | Method of using eukaryotic expression vectors comprising the BK virus enhancer | |
EP0245949B1 (fr) | Méthode d'utilisation des vecteurs d'expression eucaryotiques comportant les séquences stimulantes du virus BK | |
US5326700A (en) | DNA sequences encoding t-PA derivatives with cleavable sites | |
EP0363127B1 (fr) | Expression dans des eucaryotes | |
EP0584845B1 (fr) | Méthode d'utilisation des vecteurs d'expression eucaryotiques comportant les séquences stimulantes du virus BK | |
EP0247843A2 (fr) | Protéine S humaine, une protéine qui régularise l'hémostasie |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FF | Patent granted | ||
KB | Patent renewed | ||
KB | Patent renewed | ||
KB | Patent renewed | ||
EXTP | Application for extension order is pending | ||
KB | Patent renewed | ||
MM9K | Patent not in force due to non-payment of renewal fees |